ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A comprehensive computational analysis to explore the importance of SIGLECs in HCC biology

Yao, Senbang; Chen, Wenjun; Chen, Tingting; Zuo, He; Bi, Ziran; Zhang, Xiuqing; Pang, Lulian; Jing, Yanyan; Yin, Xiangxiang; Cheng, Huaidong*安徽医科大学; 南方医科大学
BMC GASTROENTEROLOGY2023-2-18DOI: 10.1186/s12876-023-02672-z
1被引6阅读
引用收藏
分享

摘要

BackgroundHepatocellular carcinoma (HCC) is an aggressive, malignant cancer with a complex pathogenesis. However, effective therapeutic targets and prognostic biomarkers are limited. Sorafenib provides delaying cancer progression and survival improvement in advanced HCC. But despite 10 years of research on the clinical application of sorafenib, predictive markers for its therapeutic effect are lacking.MethodsThe clinical significance and molecular functions of SIGLEC family members were assessed by a comprehensive bioinformatic analysis. The datasets included in this study (ICGC-LIRI-JP, GSE22058 and GSE14520) are mainly based on patients with HBV infections or HBV-related liver cirrhosis. The TCGA, GEO, and HCCDB databases were used to explore the expression of SIGLEC family genes in HCC. The Kaplan-Meier Plotter database was used to evaluate relationships between the expression levels of SIGLEC family genes and prognosis. Associations between differentially expressed genes in the SIGLEC family and tumour-associated immune cells were evaluated using TIMER.ResultsThe mRNA levels of most SIGLEC family genes were significantly lower in HCC than in normal tissues. Low protein and mRNA expression levels of SIGLECs were strongly correlated with tumour grade and clinical cancer stage in patients with HCC. Tumour-related SIGLEC family genes were associated with tumour immune infiltrating cells. High SIGLEC expression was significantly related to a better prognosis in patients with advanced HCC treated with sorafenib.ConclusionsSIGLEC family genes have potential prognostic value in HCC and may contribute to the regulation of cancer progression and immune cell infiltration. More importantly, our results revealed that SIGLEC family gene expression may be used as a prognostic marker for HCC patients treated with sorafenib.

学科与关键词

关键词
Hepatocellular carcinomaSorafenibPrognostic markersImmunotherapyTumour progression
相关
加载中…
  • Ahypoxia-related signature enhances the prediction of the prognosis in hepatocellular carcinoma patients and correlates with sorafenib treatment response
    Jiang, Hong-Ye; Ning, Gang; Wang, Yen-Sheng; Lv, Wei-Biao*American Journal of Translational Research, 2020, 12(12): 7762-7781.被引 14
  • ANP32 Family as Diagnostic, Prognostic, and Therapeutic Biomarker Related to Immune Infiltrates in Hepatocellular Carcinoma
    Liu, Xuxu; He, Yuanhang; Wang, Pengfei; Hu, Jie; Hao, Chenjun; Wang, Qiang; Yang, Yang; Sun, Yuanyuan; Ma, Biao; Sun, Hezheng; Xue, Dongbo*; Meng, Xianzhi*DISEASE MARKERS, 2022, 2022: 5791471.被引 1
  • A Comprehensive Prognostic and Immunological Analysis of a New Three-Gene Signature in Hepatocellular Carcinoma
    Liu, Jun; Lu, Jianjun; Li, Wenli*2021, 2021: 5546032.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC GASTROENTEROLOGY
发表日期
2023-02-18
卷期
第 23 卷, 第 1 期
页码
42
DOI
10.1186/s12876-023-02672-z
语言
ENGLISH
成果收录
SCIE

作者

  • Y

    Yao, Senbang (第一作者)

    2 · anhui med univ

  • C

    Chen, Wenjun

    anhui med univ

查看全部 10 位作者收起作者
  • C

    Chen, Tingting

    2 · anhui med univ

  • Z

    Zuo, He

    anhui med univ · 2

  • B

    Bi, Ziran

    anhui med univ · 2

  • Z

    Zhang, Xiuqing

    2 · anhui med univ

  • P

    Pang, Lulian

    anhui med univ · 2

  • J

    Jing, Yanyan

    anhui med univ · 2

  • Y

    Yin, Xiangxiang

    2 · anhui med univ

  • C

    Cheng, Huaidong (通讯)

    2 · anhui med univ · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417